Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US

Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US

MT newswireMT newswire2026/09/17 11:54
07:54 AM EDT, 09/17/2026 (MT Newswires) -- Kamada (KMDA) confirmed that it maintains "sufficient" supply and manufacturing capacity for its KedRAB anti-rabies immunoglobulin product to meet increasing demand in the US, the company said Thursday. The confirmation follows the US Centers for Disease Control and Prevention's recent advisory on the "significant" increase in human rabies exposures and subsequent use of rabies post-exposure prophylaxis, the company said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

UK productivity has been "underestimated"! Growth rate since the financial crisis revised up to 1.3%, nearly double the previous record

A new methodology released by the UK's Office for National Statistics (ONS) on Thursday indicates that the country's productivity performance since the global financial crisis has been stronger than previously estimated, as statisticians found that working hours had been overestimated.

智通财经2026/09/17 12:11